Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-07-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
关于获得阿达木单抗注射液《药品补充申请批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 百奥泰生物制药股份有限公司 regarding the receipt of an official approval notice from the National Medical Products Administration (国家药品监督管理局) for a supplemental drug application. It details the approval of a new indication for a drug (阿达木单抗注射液) and discusses the impact and risks related to this approval. The document is short (1165 characters) and is an announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is a regulatory announcement about a drug approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2020-07-28 Chinese
2020年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2020 Second Extraordinary General Meeting of Shareholders" of 百奥泰生物制药股份有限公司 (Bio-Thera Solutions Ltd.). It contains detailed meeting notices, agenda, and multiple proposals to be discussed and voted on during the shareholders' meeting. The content includes procedural rules, voting instructions, and detailed proposals such as amendments to the company charter, election of independent directors, appointment of auditors, and plans for issuing H shares and listing on the Hong Kong Stock Exchange. The document is extensive (15,000 characters) and is clearly the meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. It is not an announcement of voting results (DVA), nor a proxy solicitation (PSI), nor a regulatory filing (RNS). It is not a full annual or interim report, nor an earnings release. Therefore, the correct classification is AGM Information (AGM-R).
2020-07-22 Chinese
关于召开2020年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2020 second extraordinary general meeting of shareholders (临时股东大会) for 百奥泰生物制药股份有限公司. It includes information about the meeting date, voting methods, agenda items, voting procedures, and proxy forms. The content focuses on the announcement and procedural details of the shareholder meeting rather than the results of the meeting or the minutes. There is no indication that this is a report of voting results or a proxy solicitation document. It is not an annual or interim report, earnings release, or any financial statement. The document is a formal announcement and notice for the shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained voting results, but it does not. It also does not fit Proxy Solicitation & Information Statement (PSI) because it does not solicit votes but rather notifies about the meeting and voting procedures. The best fitting category is AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholder meetings. Since this is a notice for a shareholder meeting with detailed agenda and voting instructions, AGM Information (AGM-R) is the most appropriate classification. The document length is sufficient and the content is substantive, not a brief announcement or regulatory filing. Confidence is high due to clear meeting notice content and detailed agenda.
2020-07-13 Chinese
股东大会议事规则
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of 百奥泰生物制药股份有限公司. It extensively details the organization, management, procedures, rights, and responsibilities related to the shareholders' meetings, including the calling, proposals, voting, and resolutions of the shareholders' meetings. It references relevant laws and listing rules but does not contain financial statements, audit results, or earnings data. It is a governance document outlining internal rules and procedures for shareholder meetings rather than a report or announcement of financial results or voting outcomes. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, not a brief announcement or a report publication notice.
2020-07-13 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors". It contains detailed provisions about the composition, duties, meeting procedures, voting, and responsibilities of the board of directors. It references relevant laws, regulations, and listing rules, and outlines governance practices related to the board. There is no indication that this is a financial report, audit report, earnings release, or any other type of financial filing. Instead, it is a governance document detailing internal rules and procedures for the board. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance content, supporting a high confidence in this classification.
2020-07-13 Chinese
独立董事关于第一届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding matters discussed at the 17th meeting of the first board of directors of 百奥泰生物制药股份有限公司. It includes opinions on proposals such as the election of an independent non-executive director and the appointment/change of audit firms for the 2020 fiscal year. The document is not a full audit report or annual report but rather an opinion related to board meeting agenda items, specifically about audit firm appointments and director nominations. It is a governance-related document reflecting board/management information and decisions. The document length is short (1357 characters), and it contains detailed opinions on board matters rather than just announcements or certifications. Therefore, the best fitting category is Board/Management Information (MANG).
2020-07-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.